Procedure of the Annual General Meeting
Tweet
Share
E-mailANNOUNCEMENT NO. 277
10 October 2024
Procedure of the Annual General Meeting
The Annual General Meeting of ChemoMetec A/S was held on 10 October 2024 at 5.30 p.m. at Nordsjællands KonferenceCenter.
At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2023/24 was approved, and the Board of Directors and the Executive Board were granted discharge.
The Annual General Meeting approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1.
Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup and Peter Reich were re-elected to the Board of Directors.
Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.
The Annual General Meeting approved the remuneration policy and the remuneration report, presented by the Board of Directors.
The proposal presented by the Board of Directors that the Board of Directors be granted authority to acquire treasury shares in the Company on behalf of the Company, was approved.
There were no other items for consideration, after which the general meeting was adjourned.
After the general meeting, a constituent board meeting was held, where Niels Thestrup was re-elected as chairman and Martin Glensbjerg was re-elected as deputy chairman.
More information
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
- Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Regenx Announces Non-Brokered Financing for Gross Proceeds of $720,000
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Dividend, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
